MDs slash some drug co. ties amid rising scrutiny

November 8, 2010 By LINDSEY TANNER , AP Medical Writer

(AP) -- A survey shows doctors have sharply cut some financial ties to drug companies, thanks to increased scrutiny about those relationships.

Critics say drug company payments and freebies improperly influence .

The survey says the biggest change is in the number of doctors taking drug company money for attending medical meetings. Last year just 18 percent of doctors surveyed said they accepted those payments, versus 35 percent in 2004.

There was also a drop from 78 percent to almost 64 percent among doctors who accepted free drug samples. Patients may like getting free medicine, but those samples can affect doctors' prescribing habits.

Almost 2,000 were surveyed. The results appear in Monday's .

More information: Arch Intern Med. 2010;170[20]:1820-1826.


Related Stories

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.